HUP9801767A3 - Viral vectors their use for treating hyperproliferative disorders, in particular restenosis - Google Patents

Viral vectors their use for treating hyperproliferative disorders, in particular restenosis

Info

Publication number
HUP9801767A3
HUP9801767A3 HU9801767A HUP9801767A HUP9801767A3 HU P9801767 A3 HUP9801767 A3 HU P9801767A3 HU 9801767 A HU9801767 A HU 9801767A HU P9801767 A HUP9801767 A HU P9801767A HU P9801767 A3 HUP9801767 A3 HU P9801767A3
Authority
HU
Hungary
Prior art keywords
viral vectors
hyperproliferative disorders
treating hyperproliferative
particular restenosis
restenosis
Prior art date
Application number
HU9801767A
Other languages
English (en)
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of HUP9801767A2 publication Critical patent/HUP9801767A2/hu
Publication of HUP9801767A3 publication Critical patent/HUP9801767A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9801767A 1995-03-31 1996-03-28 Viral vectors their use for treating hyperproliferative disorders, in particular restenosis HUP9801767A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9504234A FR2732357B1 (fr) 1995-03-31 1995-03-31 Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose

Publications (2)

Publication Number Publication Date
HUP9801767A2 HUP9801767A2 (hu) 1998-10-28
HUP9801767A3 true HUP9801767A3 (en) 1999-04-28

Family

ID=9477928

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801767A HUP9801767A3 (en) 1995-03-31 1996-03-28 Viral vectors their use for treating hyperproliferative disorders, in particular restenosis

Country Status (16)

Country Link
US (2) US5851521A (hu)
EP (1) EP0817791A4 (hu)
JP (1) JPH11503314A (hu)
KR (1) KR19980703454A (hu)
CN (1) CN1190402A (hu)
AP (1) AP1011A (hu)
AU (1) AU701345B2 (hu)
BR (1) BR9608449A (hu)
CA (1) CA2216878A1 (hu)
CZ (1) CZ308897A3 (hu)
FR (1) FR2732357B1 (hu)
HU (1) HUP9801767A3 (hu)
OA (1) OA10516A (hu)
SI (1) SI9620059A (hu)
SK (1) SK132797A3 (hu)
WO (1) WO1996030385A1 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
FR2740344B1 (fr) * 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers
FR2754822B1 (fr) * 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
AU3347000A (en) 1999-01-19 2000-08-01 Children's Hospital Of Philadelphia, The Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
ATE460951T1 (de) 2000-01-25 2010-04-15 Edwards Lifesciences Corp Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie
DE60131146T2 (de) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US20030100889A1 (en) * 2001-07-05 2003-05-29 Nicolas Duverger Method of administration of a gene of interest to a vascular tissue
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
US20080215137A1 (en) * 2003-04-30 2008-09-04 Boston Scientific Scimed, Inc. Therapeutic driving layer for a medical device
US20040220656A1 (en) * 2003-04-30 2004-11-04 Epstein Samuel J. Coated medical devices and methods of making the same
AU2004272114B2 (en) * 2003-09-12 2010-11-04 Vertex Pharmaceuticals Incorporated Animal model for protease activity and liver damage
AU2005222384A1 (en) 2004-03-05 2005-09-22 Vegenics Limited Growth factor binding constructs materials and methods
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) * 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
FI20050753A (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
EP1853628B1 (en) * 2005-02-17 2015-08-19 Vertex Pharmaceuticals Incorporated Sodium channel protein type iiii alpha-subunit splice variant
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
WO2007136679A2 (en) 2006-05-17 2007-11-29 Ludwig Institute For Cancer Research Targeting vegf-b regulation of fatty acid transporters to modulate human diseases
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
JP5309159B2 (ja) 2008-01-09 2013-10-09 コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション バキュロウイルスを利用したワクチン
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US8052970B2 (en) * 2008-06-30 2011-11-08 The Regents Of The University Of Michigan Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
US8871509B2 (en) 2009-11-06 2014-10-28 Chung-Ang University-Academy Corporation Foundation Nanoparticle-based gene delivery systems
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
WO2012158989A2 (en) 2011-05-19 2012-11-22 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
KR101427200B1 (ko) 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
DK2785683T3 (da) 2011-11-30 2020-04-14 Ludwig Inst For Cancer Res Ltd Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
SI2892617T1 (sl) 2012-09-06 2018-11-30 The University Of Chicago Protismiselni polinukleotidi za zagotavljanje preskakovanja eksonov in postopki zdravljenja distrofij
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
JP6408492B2 (ja) 2013-02-18 2018-10-17 ヴェジェニクス プロプライエタリー リミテッドＶｅｇｅｎｉｃｓ Ｐｔｙ Ｌｉｍｉｔｅｄ リガンド結合分子およびその使用
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
EP3283500B1 (en) 2015-04-08 2020-11-11 The University of Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
CN108289920A (zh) 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
MX2019003158A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Vectores de adenovirus canino.
CN110072546B (zh) 2016-09-20 2023-10-31 勃林格殷格翰动物保健有限公司 新的猪流感疫苗
TWI817933B (zh) 2016-09-20 2023-10-11 德商百靈佳殷格翰維美迪加股份有限公司 新穎ehv插入位點orf70
CN109790550B (zh) 2016-09-20 2024-02-09 勃林格殷格翰动物保健有限公司 新颖的启动子
SG11202005509YA (en) 2017-12-13 2020-07-29 Genemedicine Co Ltd Recombinant adenoviruses and stem cells comprising same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
CA1339354C (en) * 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
JPH08503855A (ja) * 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
BR9405507A (pt) * 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene

Also Published As

Publication number Publication date
JPH11503314A (ja) 1999-03-26
BR9608449A (pt) 1999-11-30
MX9707549A (es) 1998-07-31
FR2732357A1 (fr) 1996-10-04
USRE37933E1 (en) 2002-12-10
EP0817791A1 (en) 1998-01-14
AP9701117A0 (en) 1996-03-28
AP1011A (en) 2001-09-22
CN1190402A (zh) 1998-08-12
CZ308897A3 (cs) 1998-03-18
WO1996030385A1 (en) 1996-10-03
HUP9801767A2 (hu) 1998-10-28
SK132797A3 (en) 1998-07-08
CA2216878A1 (en) 1996-10-03
FR2732357B1 (fr) 1997-04-30
EP0817791A4 (en) 1998-07-15
KR19980703454A (ko) 1998-11-05
US5851521A (en) 1998-12-22
AU5531596A (en) 1996-10-16
AU701345B2 (en) 1999-01-28
OA10516A (en) 2002-04-22
SI9620059A (sl) 1998-06-30

Similar Documents

Publication Publication Date Title
HUP9801767A3 (en) Viral vectors their use for treating hyperproliferative disorders, in particular restenosis
GB2304196B (en) Electroconvulsive therapy
GB2298440B (en) Well treatment
DE69628446D1 (en) Polycarbonatharz, vernetztes polycarbonatharz und elektrophotographischer photorezeptor
GB9519033D0 (en) Treatment
GB9712205D0 (en) Body belt
ZA9810405B (en) Process for treating foods
HU9700595D0 (en) Fluoro-alkyl- and fluoro-alkoxy-substituted heterocyclic bradiquinine-antagonists, process for producing them and their use
GB2326097B (en) Apparatus for treating the eyes physically
HUT69056A (en) Cyclic-acetals, process for their preparation and their use as herbicides
ZA965191B (en) Cell treatment
PL321699A1 (en) Tempering process
ZA964198B (en) Treatment regime for skin.
KR19987002519A (en) Process for subsequent codensation of polycondensates , in particular of poyamide 6.6
ZA971217B (en) Diamond treatment.
AU2099095A (en) Ribozyme therapy for restenosis
ZA9810673B (en) 1-methyl-5-alkysulfonyl-, 1-methyl-5-alkylsulfinyl- and 1-methyl-5-alkylthio-substituted pyrazolylpyrazoles, process for their preparation and their use as herbicides
KR0110233Y1 (en) Leather belt
GB2322785B (en) Pasteurizing process
SG73455A1 (en) Apparatus for treating the eyes physically
EP0664129A3 (en) Epicholesterol used to treat dyslipemia.
GB9524474D0 (en) Anti-static treatment
AUPM529594A0 (en) Process for treating nickel concentrates
GB9420051D0 (en) Infertility treatment
GB2291245B (en) Process for tuning the interconnection strengths in artificial neural networks